ISTH interim guidance on recognition and management of coagulopathy in COVID-19
The COVID-19 outbreak has now spread worldwide, and the number of severe cases is increasing exponentially. Besides the...
Most Read
Real-world CAT patient profile from the RIETE registry
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?”, Dr. Laurent Bertoletti gave a...
An Overview of VTE Prevention and Management in Gynecological Cancer Care
As with cancers in general, gynecological cancers also exhibit a clear and increasingly significant association with...
Thrombocytopenia and management of anticoagulation in the patient with thrombosis and cancer
Cancer-associated thrombosis (CAT) presents a unique and multifaceted challenge in clinical practice, particularly in...
Looking for a reliable tool to identify hypercoagulant markers for cancer risk and prognosis: the HYPERCAN study
The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...
Management of CAT: Lung Cancer Focus
Our speakers, Nicolas Girard and António Araújo shared some insights on the management of...
Isolated Distal DVT In Cancer Patients: What Do Recent Studies Suggest?
In a recent issue of the Journal of Thrombosis and Hemostasis, we report that cancer patients with isolated distal deep...
miRNA and its role in cancer-associated thrombosis
Cancer-associated thrombosis (CAT) is one of the leading causes of non-cancer-related deaths in patients with cancer...
Update on Oncology & Thrombosis to include COVID‐19
In this webinar, our speakers Dr. Carme Font, Prof. Tzu-Fei Wang, and Prof. Marc Carrier talked about the recent...
The Combined Impact of Serum Albumin and Genetic Risk on VTE: Implications for Early Prevention
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most...